Share:
Peer-Reviewed Publication
Sci Rep2026July 20, 2026Journal Article

Selective portal vein occlusion and myocardial injury after major hepatobiliary surgery: a propensity-weighted cohort study.

Yi Duan1, Zheng Zhang1, Jinyan Wei1, Qinzheng Wen1, Lin Ding2, Yuze Wang1, Qian Lu3,4,5,6, Zhifeng Gao7
1Department of Anesthesiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China.
2Department of Anesthesiology, Peking University International Hospital, Beijing, 102216, China.
3Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Organ Transplantation Center, Tsinghua University, Beijing, 102218, China.
4Key Laboratory of Digital Intelligence Hepatology (Chinese Ministry of Education), School of Clinical Medicine, Tsinghua University, Beijing, 100084, China.
5Research Unit of Precision Hepatobiliary Surgery Paradigm, Chinese Academy of Medical Sciences, Beijing, 100010, China.
6Institute for Organ Transplantation and Bionics, Institute for Precision Medicine, School of Clinical Medicine, Tsinghua University, Beijing, 100010, China.
7Department of Anesthesiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China. btchgzf@hotmail.com.

Abstract

Hepatic inflow occlusion is central to major hepatobiliary surgery, but its association with early postoperative myocardial injury remains uncertain. We evaluated whether selective portal vein occlusion (SPVO), which preserves hepatic arterial flow, was associated with myocardial injury after noncardiac surgery (MINS) compared with the Pringle maneuver. This multicenter retrospective-prospective o…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.